Futura Signs Joint Venture Collaboration To Explore Transdermal Delivery of Cannabidiol DermaSys®

Futura签署合资企业合作协议,发展大麻Dermasys透皮给药技术

2019-09-16 08:30:13 BioSpace

本文共1281个字,阅读需4分钟

Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce a joint venture collaboration with CBDerma Technology Limited to explore the application of Futura’s advanced proprietary transdermal drug delivery technology, DermaSys® for delivery of Cannabidiol. All Intellectual Property will be owned jointly by the Company and CBDerma Technology Limited. CBDerma Technology is a company that has been established and funded to specifically exploit the therapeutic potential of Cannabis. The company’s management, backers and advisors have extensive knowledge, expertise and investments in plant derived product manufacturing. Cannabidiol is a major component of the cannabis plant and is generally regarded as non-addictive and non-psychoactive, making it ideal for consideration as a topically delivered molecule for local or regional (non-systemic) use. Initial development costs are expected to be in the region of US$ 1 million and will cover all development costs incurred by the Company during the next 15 months in order to develop and optimise a DermaSys®- cannabidiol formulation as well as establishing early ex-vivo proof of concept studies likely to include certain disease states most suited for local or regional (non-systemic) topical treatment such as pain relief. The Company does not expect this project’s initial development to have any material impact on cashflow as Futura’s financial share of the project will be delivered from its expertise and existing internal resources. DermaSys® provides rapid and targeted local delivery of active pharmaceutical ingredients at therapeutic levels through the skin to the required site of action with a high level of safety. It is a versatile and bespoke technology that can be tailored to suit the specific active compound being used and the therapeutic indication. Each product is formulated to maximise its benefits for patients and consumers and can be developed for the prescription and consumer healthcare markets as appropriate. James Barder, CEO of Futura Medical said: “Futura’s core strength lies in our research and development capabilities, particularly in the application of our proprietary Dermasys® transdermal delivery system which enables targeted and controlled delivery of drugs through the skin. The benefits and applications of cannabis and cannabidiol in both the medical and consumer markets are well known and expanding rapidly. However, optimised and targeted topical delivery of the active ingredients remains a problem. We believe that our Dermasys® technology has the potential to solve these issues, advancing product development and expanding indications and use of Cannabidiol.” About Futura Medical plc Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk. The first European Phase 3 study for MED2005, referred to as “FM57”, is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
Futura Medical(AIM:FUM)(以下简称“公司”)是一家制药公司,基于其专有的经皮Dermasys®药物递送技术开发一系列创新产品,目前专注于性健康和性疼痛,很高兴宣布与ITH CBderma Technology Limited将探索Futura先进的专有透皮给药技术Dermasys®在给药Cannabidiol中的应用。所有知识产权将由公司和CBderma科技有限公司共同拥有。 CBderma Technology是一家专门开发大麻治疗潜力的公司。公司的管理层、支持者和顾问在工厂衍生产品制造方面拥有广泛的知识、专业知识和投资。大麻酚是大麻植物的主要成分,通常被认为是非成瘾性和非精神活性的,是局部或区域(非系统性)使用的局部投递分子。 初步开发成本预计在100万美元左右,并将涵盖公司在未来15个月内发生的所有开发成本,以便开发和优化Dermasys-Cannabidiol配方,以及建立早期的体外概念验证研究。瘢痕疙瘩包括某些最适合局部或局部(非系统性)局部治疗的疾病状态,如疼痛缓解。公司预计,该项目的初步开发不会对现金流产生任何实质性影响,因为Futura在该项目中的财务份额将由其专业知识和现有内部资源提供。 Dermasys通过皮肤将治疗水平的活性药物成分快速、有针对性地局部输送到所需的作用部位,具有高度的安全性。它是一种多用途的定制技术,可以根据所使用的特定活性化合物和治疗适应症进行定制。每种产品的制定都是为了最大限度地为患者和消费者带来利益,并可根据需要为处方药和消费者健康市场开发。 futura medical首席执行官詹姆斯巴德(james barder)表示:futura的核心优势在于我们的研发能力,特别是我们专有的dermasys透皮给药系统的应用,该系统允许药物通过皮肤有针对性地、有控制地给药。大麻和大麻比妥尔在医疗和消费市场的益处和应用是众所周知的,并迅速扩大。然而,优化和有针对性的局部递送活性成分仍然是一个问题。我们相信,我们的Dermasys技术有潜力解决这些问题,促进产品开发,扩大适应症和cannabidiol的使用。 关于Futura医疗公司。 futura medical plc(aim:fum)是一家制药公司,基于其专有的经皮皮肤给药技术开发一系列创新产品。这些产品针对临床疗效、安全性、给药和患者方便性进行了优化,并根据需要为处方药和消费者健康市场开发。目前的治疗领域是性健康,包括勃起功能障碍和疼痛缓解。开发和商业化战略旨在最大化产品差异化和价值创造,同时最小化风险。 MED2005的第一个欧洲3期研究,称为FM57,是一项1000名患者、剂量范围、多中心、随机、双盲、安慰剂对照、家庭使用的MED2005 0.2%、0.4%和0.6%硝酸甘油治疗勃起功能障碍的平行组研究。开放标签FM57进展顺利,预计2019年底将公布主要数据。 futura总部位于萨里郡吉尔福德,其股票在伦敦证券交易所aim市场交易。www.futuramedical.com未来医学网

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文